Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials-Reference-Cited by-同舟云学术

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials

Published:2022-01-31 Issue: Volume: Page:
ISSN:2042-6976
Container-title:International Forum of Allergy & Rhinology
language:en
Short-container-title:Int Forum Allergy Rhinol

Author:

Bachert Claus¹²³,Corren Jonathan⁴,Lee Stella E.⁵,Zhang Haixin⁶,Harel Sivan⁶,Cunoosamy Danen⁷,Khan Asif H.⁸,Jacob‐Nara Juby A.⁹,Siddiqui Shahid⁶,Nash Scott⁶,Rowe Paul J.⁹,Deniz Yamo⁶

Affiliation:

1. Ghent University Ghent Belgium

2. Karolinska Institutet Stockholm Sweden

3. Sun Yat‐sen University, The First Affiliated Hospital Guangzhou China

4. David Geffen School of Medicine at UCLA Los Angeles California USA

5. Division of Otolaryngology—Head and Neck Surgery Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA

6. Regeneron Pharmaceuticals, Inc. Tarrytown New York USA

7. Sanofi Cambridge Massachusetts USA

8. Sanofi Chilly‐Mazarin France

9. Sanofi, Bridgewater New Jersey USA

Publisher

Wiley